Evidence of Inbreeding Depression on Human Height

Ruth McQuillan\textsuperscript{1}, Niina Eklund\textsuperscript{2,3}, Nicola Pirastu\textsuperscript{4}, Maris Kuningas\textsuperscript{5}, Brian P. McEvoy\textsuperscript{6}, Tõnu Esko\textsuperscript{1}, Tanguy Corre\textsuperscript{9}, Gail Davies\textsuperscript{10}, Marika Kaakinen\textsuperscript{11,12}, Leo-Pekka Lytykäinen\textsuperscript{13,14}, Kati Kristiansson\textsuperscript{2,3}, Aki S. Havulinna\textsuperscript{3}, Martin Gögele\textsuperscript{15}, Veronique Vitart\textsuperscript{16}, Albert Tenesa\textsuperscript{16,17}, Yuriu Aulchenko\textsuperscript{18}, Caroline Hayward\textsuperscript{16}, Åsa Johansson\textsuperscript{19}, Mladen Boban\textsuperscript{20}, Sheila Ulivi\textsuperscript{21}, Antonietta Robino\textsuperscript{4}, Vesna Boraska\textsuperscript{22}, Wilmar Igl\textsuperscript{23}, Sarah H. Wild\textsuperscript{1}, Lina Zgaga\textsuperscript{1,24}, Najaf Amin\textsuperscript{18}, Evropi Theodoratou\textsuperscript{1}, Ozren Polasek\textsuperscript{25,26}, Giorgia Girotto\textsuperscript{4}, Lorna M. Lopez\textsuperscript{10,27}, Cinzia Sala\textsuperscript{9}, Jari Lahti\textsuperscript{28}, Tiina Laatikainen\textsuperscript{3}, Inga Prokopenko\textsuperscript{29,30}, Mart Kals\textsuperscript{7}, Jorma Viikari\textsuperscript{31,32}, Jian Yang\textsuperscript{6}, Anneli Pouta\textsuperscript{33}, Karol Estrada\textsuperscript{34,35}, Albert Hofman\textsuperscript{3,5}, Nelson Freimer\textsuperscript{36,37,38}, Nicholas G. Martin\textsuperscript{6}, Mika Kähönen\textsuperscript{39,40}, Lili Milan\textsuperscript{7}, Markku Heliovaara\textsuperscript{41}, Erkki Vartiainen\textsuperscript{42}, Katri Räikkönen\textsuperscript{28}, Corrado Masiullo\textsuperscript{9}, John M. Starr\textsuperscript{27,43}, Andrew A. Hicks\textsuperscript{15}, Laura Esposito\textsuperscript{44}, Ivana Kolčić\textsuperscript{25,26}, Susan M. Farrington\textsuperscript{45}, Ben Oostra\textsuperscript{46}, Tatijana Zemunik\textsuperscript{22}, Harry Campbell\textsuperscript{1}, Mirna Kirin\textsuperscript{1}, Marina Pehlic\textsuperscript{22}, Flavio Faletre\textsuperscript{21}, David Porteous\textsuperscript{27,47}, Giorgio Pistis\textsuperscript{9}, Elisabeth Widén\textsuperscript{2}, Veikko Salomaa\textsuperscript{3}, Seppo Koskinen\textsuperscript{48}, Krista Fischer\textsuperscript{7}, Terho Lehtimäki\textsuperscript{3,14}, Andrew Heath\textsuperscript{49}, Mark I. McCarthy\textsuperscript{29,30,50}, Fernando Rivadeneira\textsuperscript{5,34,35}, Grant W. Montgomery\textsuperscript{6}, Henning Tiemeier\textsuperscript{5,35,51}, Anna-Liisa Hartikainen\textsuperscript{52}, Pamela A. F. Madden\textsuperscript{49}, Pio d’Adamo\textsuperscript{4}, Nicholas D. Hastie\textsuperscript{16}, Ulf Gyllensten\textsuperscript{73}, Alan F. Wright\textsuperscript{16}, Cornelia M. van Duijn\textsuperscript{18,35}, Malcolm Dunlop\textsuperscript{45}, Igor Rudan\textsuperscript{1}, Paolo Gasparini\textsuperscript{4}, Peter P. Pramstaller\textsuperscript{15,53,54}, Ian J. Deary\textsuperscript{10,27}, Daniela Toniolo\textsuperscript{9,55}, Johan G. Eriksson\textsuperscript{3,56,57,58}, Antti Jula\textsuperscript{5}, Olli T. Raitakari\textsuperscript{59,60}, Andres Metspalu\textsuperscript{7,8}, Markus Perola\textsuperscript{2,3,7}, Marjo-Riitta Järvelin\textsuperscript{11,12,33,61}, André Uitterlinden\textsuperscript{5,34,35}, Peter M. Visscher\textsuperscript{6}, James F. Wilson\textsuperscript{11} on behalf of the ROHgen Consortium

1Centre for Population Health Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 2Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland, 3Department of Chronic Population Prevention, National Institute for Health and Welfare, Helsinki, Finland, 4Institute for Maternal and Child Health, ICRCS “Burlo Garofolo,” University of Trieste, Trieste, Italy, 5Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands, 6Queensland Institute of Medical Research, Brisbane, Queensland, Australia, 7Essex Genome Center, University of Tartu, Tartu, Estonia, 8Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia, 9Division of Genetics and Cell Biology, San Raffaele Research Institute, Milan, Italy, 10Department of Psychology, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 11Biocenter Oulu, University of Oulu, Oulu, Finland, 12Institute of Health Sciences, University of Oulu, Oulu, Finland, 13Department of Clinical Chemistry, Tampere University Hospital, Tampere, Finland, 14Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland, 15Centre for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy, 16MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 17The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, Scotland, United Kingdom, 18Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands, 19Upplandska Clinical Research, Uppsala University, Uppsala, Sweden, 20Department of Pharmacology, Faculty of Medicine, University of Split, Split, Croatia, 21Institute for Maternal and Child Health, ICRCS “Burlo Garofolo,” Trieste, Italy, 22Department of Biology, Faculty of Medicine, University of Split, Split, Croatia, 23Department of Immunology, Genetics and Pathology, SciLifeLab Uppsala, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden, 24Andrija Stampar School of Public Health, Medical School, University of Zagreb, Zagreb, Croatia, 25Department of Clinical Medicine, Faculty of Medicine, University of Split, Split, Croatia, 26Centre for Global Health, University of Split, Split, Croatia, 27Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 28Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland, 29Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom, 30Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 31Department of Medicine, Turku University Hospital, Turku, Finland, 32Department of Medicine, University of Turku, Turku, Finland, 33National Institute for Health and Welfare, Oulu, Finland, 34Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, 35Netherlands Genomics Initiative (NGI)—sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands, 36Brain Research Institute, University of California Los Angeles, Los Angeles, California, United States of America, 37UCCLA Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, California, United States of America, 38Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, United States of America, 39Department of Clinical Psychology, Tampere University Hospital, Tampere, Finland, 40Department of Clinical Psychology, University of Tampere School of Medicine, Tampere, Finland, 41Department of Health and Functional Capacity, National Public Health Institute–Helsinki and Turku, Turku, Finland, 42Division of Welfare and Health Promotion, National Institute for Health and Welfare, Helsinki, Finland, 43Geriatric Medicine Unit, University of Edinburgh, Royal Victoria Hospital, Edinburgh, Scotland, United Kingdom, 44CBM scrl – Genomics, Area Science Park, Basovizza, Trieste, Italy, 45Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, United Kingdom, 46Genetic Epidemiology Unit, Department of Clinical Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands, 47Medical Genetics Section, The University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland, United Kingdom, 48Department of Health and Functional Capacity, National Public Health Institute, Helsinki, Finland, 49Department of Psychiatry, Washington University St. Louis, Missouri, United States of America, 50Oxford NIHR Biomedical Research Centre, Churchill Hospital, Headington, Oxford, United Kingdom, 51Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands, 52Institute of Clinical Medicine/Obstetrics and Gynecology, University of Oulu, Oulu, Finland, 53Department of Neurology, General Central Hospital, Bolzano, Italy, 54Department of Neurology, University of Lübeck, Lübeck, Germany, 55Institute of Molecular Genetics–CRN, Pavia, Italy, 56Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland, 57Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland, 58Folkhälsan Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland, 59Department of Clinical Physiology, Turku University Hospital, Turku, Finland, 60Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom.
Introduction

Height is a classic complex trait, which is influenced by both genetic and non-genetic factors. Observed increases in height in developed countries over the last few generations suggest that environmental factors such as nutrition and childhood healthcare play an important role in determining adult height [1,2]. Within any one population at one point in time, 80–90% of the variation in height is explained by genetic factors [3,4,5,6,7,8]. These characteristics, plus the fact that height is cheaply and accurately measurable and has been assessed in many thousands of study subjects, make it an attractive model for investigating the genetic architecture of quantitative traits generally [9,10]. Height is not merely of interest as a model quantitative trait (QT): a better understanding of the genetic mechanisms influencing height offers insights into genetic variants influencing growth and development [11]. Because height is associated with a range of complex diseases, including cancer, [12,13,14,15] and because pleiotropic effects have been observed between disease-associated and height-associated genetic variants [16,17,18], a better understanding of the genetic mechanisms influencing height may also provide biological insights into disease mechanisms.

In a seminal work published almost a century ago, Fisher first proposed that the heritability of height results from the combined effects of many genetic variants of individually small effect size [19]. In recent years, the advent of genome-wide association studies (GWAS) has enabled this theory to be tested empirically. A GWAS of over 180,000 individuals conducted by the GIANT

Abstract

Stature is a classical and highly heritable complex trait, with 80%–90% of the variation explained by genetic factors. In recent years, genome-wide association studies (GWAS) have successfully identified many common additive variants influencing human height; however, little attention has been given to the potential role of recessive genetic effects. Here, we investigated genome-wide recessive effects by an analysis of inbreeding depression on adult height in over 35,000 people from 21 different population samples. We found a highly significant inverse association between height and genome-wide homozygosity, equivalent to a height reduction of up to 3 cm in the offspring of first cousins compared with the offspring of unrelated individuals, an effect which remained after controlling for the effects of socio-economic status, an important confounder ($\chi^2 = 83.89, \text{df} = 1; p = 5.2 \times 10^{-24}$). There was, however, a high degree of heterogeneity among populations: whereas the direction of the effect was consistent across most population samples, the effect size differed significantly among populations. It is likely that this reflects true biological heterogeneity: whether or not an effect can be observed will depend on both the variance in homozygosity in the population and the chance inheritance of individual recessive genotypes. These results predict that multiple, rare, recessive variants influence human height. Although this exploratory work focuses on height alone, the methodology developed is generally applicable to heritable quantitative traits (QT), paving the way for an investigation into inbreeding effects, and therefore genetic architecture, on a range of QT of biomedical importance.

Citation: McQuillan R, Eklund N, Pirastu N, Kuningas M, McEvoy BP, et al. (2012) Evidence of Inbreeding Depression on Human Height. PLoS Genet 8(7): e1002655. doi:10.1371/journal.pgen.1002655

Editor: Greg Gibson, Georgia Institute of Technology, United States of America

Received January 19, 2012; Accepted March 2, 2012; Published July 19, 2012

Copyright: © 2012 McQuillan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: CROATIA-Korcula is supported by the Medical Research Council and The Croatian Ministry of Science, Education, and Sports. CROATIA-Split is supported by the Medical Research Council and The Croatian Ministry of Science, Education, and Sports; and the EU FP6 EUROSPAN project. EGUT is funded by European Union FP7, targeted financing from the Government of Estonia and from the ministries of research and science and social affairs and EXCEGEN. ERF is supported by grants from the NWO, Erasmus MC, the Centre for Medical Systems Biology (CSMB), and the EU FP6 EUROSPAN project. FINRIS is funded by THL and by the Academy of Finland. H2000 is funded by THL, the Finnish Centre for Pensions (ETK), The Social Insurance Institution of Finland (KELA), The Local Government Pensions Institution (KEVA), and other organisations listed on the website of the survey (http://www.terveys2000.fi, accessed 2011), the Academy of Finland, and the Orion-Farmos Research Foundation. HBCS is supported by the Academy of Finland, the Finnish Diabetes Research Society, Novo Nordisk Foundation, Finnska Lakarealliansen, the European Science Foundation (EuroSTRESS), the Wellcome Trust, Samfundet Folkhalsan, and the Signe and Aune Gyllenberg Foundation. INGI-CARL is supported by Italian Ministry of Health. INGI-FVG is supported by the Italian Ministry of Health, FVG Region, and Fondo Trieste. INGI-Val Borbera is supported by the Italian Ministry of Health, Compagnia di San Paolo Foundation, and Cariplo Foundation. LBC1921 and LBC1936 are supported by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC), Research Into Ageing (continues as part of Age UK’s The Disconnected Mind project), the Lifelong Health and Wellbeing Initiative (funded by the BBSRC, EPSRC, ESRC, MRC), the Chief Scientist Office of the Scottish Government, and the AXA Research Fund. MICROs is supported by the Ministry of Health and Department of National Assistance, University and Research of the Autonomous Province of Bolzano, and the South Tyrolean Sparkasse Foundation. NFBC1966 was supported by the Academy of Finland (including Center of Excellence in Complex Disease Genetics), University Hospital Oulu, Biocenter Oulu, University of Oulu, an NHLBI grant through the STAMPEED program, ENGAGE project, the Medical Research Council (studentship grant PrevMetSyn/SAve/MRC), and the Wellcome Trust UK. The DNA extractions, sample quality controls, biobank up-keeping, and aliquoting were performed in the National Public Health Institute, Biocenter Helsinki, Finland, and were supported financially by the Academy of Finland and Biocentrum Helsinki. NSPHS is funded by the Swedish Medical Research Agency and the EU FP6 EUROPEAN project. ORCADES is supported by the Chief Scientist Office of the Scottish Executive, The Royal Society, the EU FP6 EUROSPAN project, and the MRC Human Genetics Unit. QIMR is supported by the Australian National Health and Medical Research Council and the Australian Research Council. RS is supported by the Netherlands Genomics Initiative (Netherlands Organization for Scientific Research (NWO) project; Erasmus Medical Centre and Erasmus University Rotterdam; Netherlands Organization for the Health Research and Development (ZonMW); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture, and Science; the Ministry for Health, Welfare, and Sports; the European Commission (DG XII); the Municipality of Rotterdam; Netherlands Organization of Scientific Research NWO Investments; and VIDI. The SOCCS study is supported by Cancer Research UK and the Bobby Moore Fund, by the UK Medical Research Council, and by a centre grant from CORE as part of the Digestive Cancer Campaign. YFS is supported by the Academy of Finland; the Social Insurance Institution of Finland; Kuopio, Tampere, and Turku University Hospital Medical Funds; Juho Vainio Foundation; Paavo Nummi Foundation; Finnish Foundation of Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; and Emil Aaltonen Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jim.wilson@ed.ac.uk
Inbreeding Depression on Height

**Author Summary**

Studies investigating the extent to which genetics influences human characteristics such as height have concentrated mainly on common variants of genes, where having one or two copies of a given variant influences the trait or risk of disease. This study explores whether a different type of genetic variant might also be important. We investigate the role of recessive genetic variants, where two identical copies of a variant are required to have an effect. By measuring genome-wide homozygosity—the phenomenon of inheriting two identical copies at a given point of the genome—in 35,000 individuals from 21 European populations, and by comparing this to individual height, we found that the more homozygous the genome, the shorter the individual. The offspring of first cousins (who have increased homozygosity) were predicted to be up to 3 cm shorter on average than the offspring of unrelated parents. Height is influenced by the combined effect of many recessive variants dispersed across the genome. This may also be true for other human characteristics and diseases, opening up a new way to understand how genetic variation influences our health.

(Genome-wide Investigation of Anthropometric Measures) consortium found common genetic variants at more than 180 loci influencing human height [20]. Despite the undoubted success of GWAS, even this very large study discovered variants explaining in total only around 10% of phenotypic variation [20]. This “missing heritability” [21] has become an important subject of debate in genetic epidemiology because of the implications it has for future gene discovery strategies and indirectly on attempts to predict phenotype from genotype. Yang and colleagues proposed a different approach to identifying this missing heritability [22]. Instead of using GWAS to identify individual genome-wide significant SNPs associated with stature, they considered all SNPs simultaneously, allowing the entire GWAS data to be used as predictors. Using this approach, they explained up to 40% of the variance in height. This still leaves ~40% of variance unexplained by common genetic variants. The authors of the large GIANT study cited above predict that increased GWAS sample sizes will identify more common variants of moderate-to-small effect size and will increase the proportion of heritable variation explained merely to around 20% [20,22]. Therefore, alternative strategies are required in order to detect rarer variants, structural variants, variants of very small effect size, and interactions, including dominance and epistasis [21].

This study explores whether there is evidence for genome-wide recessive genetic effects, or inbreeding depression, on height. Inbreeding depression implies directional dominance: i.e. that dominance is on average in the same direction across loci. An association between height and genome-wide homozygosity would imply that height was influenced by the combined effects of many recessive variants of individually small effect size, scattered across the genome. On the face of it, this endeavour looks unpromising. Most pedigree and GWAS studies investigating the genetic architecture of height to date have found no strong evidence of deviation from an additive genetic model [23]. Three heritability studies have found little evidence for dominance variance [24,25,26]. Absence of evidence for dominance variance need not, however, be inconsistent with evidence of inbreeding depression: it can be shown that, assuming a large number of contributing loci, it is theoretically possible to have inbreeding depression in the absence of detectable dominance variance [27].

Dominance variance may be difficult to estimate in study designs where genome-wide additive and dominance coefficients are highly correlated [26]. Independently of GWAS, epidemiologists have long observed associations between parental relatedness and reduced height [28,29,30,31], although not all studies have found such an association [32,33]. A recent small study of the isolated Norfolk Island population found an association between reduced height and both parental relatedness (estimated from genealogical data) and genome-wide homozygosity (estimated from microsatellite markers) [34]. Finally, whilst many twin studies have concluded that height is purely additive, an extended twin family design using large numbers (n = 29,891) revealed a non-additive genetic component of 9.4% which was balanced by extra additive variance due to assortative mating (confounded with shared environment in twin studies). As assortative mating increases the correlation in dizygotic twins above half that in monozygotic twins, whereas dominance does the opposite, they appear to cancel each other out, so height looks perfectly additive from twins alone [35].

The aim of this study was to explore the association between genome-wide homozygosity and adult height, controlling for the effects of potential confounding factors. The study involved over 35,000 subjects, drawn from 21 population samples. We invited studies to participate in the consortium which we knew were conducted in isolated populations, where both the mean and variance in genome-wide homozygosity are higher. In this way, we optimised our chances of being able to detect an effect, should one exist. We found highly significant evidence of an inverse association between genome-wide homozygosity and height, with significant heterogeneity among sample sets.

**Results**

We explored the association between genome-wide homozygosity and height in 21 European or European-heritage populations (Table 1). All samples were genotyped using the Illumina platform (see Materials and Methods and Supporting Information). Because different Illumina platforms were used by different studies, we extracted the SNPs present in the Illumina HumanHap 300 panel (common to all the Illumina platforms used). The number of SNPs remaining after quality control procedures had been run on a population-by-population basis are given in Table 1, as are details of the mean age and height of the samples and the proportion of women in each sample.

We used three different measures of genome-wide homozygosity. $F_{\text{ROH}}$ is defined as the percentage of the typed autosomal genome in runs of homozygosity (ROH) greater than or equal to 1.5 Mb in length. $F_{\text{ROH}}$ is strongly correlated with the degree of relatedness between an individual’s parents [36]. $F_{\text{ROH,LD}}$ is a modification of $F_{\text{ROH}}$, derived using a panel of independent SNPs, where all SNPs in strong linkage disequilibrium (LD) have been removed. This is a more stringent estimate of parental relatedness: removing SNPs that are in strong LD with other SNPs means that all ROH detected are likely to be the result of recent parental relatedness and not ancient patterns of shared ancestry. The third measure we used was observed homozygosity ($F_{\text{homo}}$). This is defined as the number of observed homozygous genotypes per individual, expressed as a percentage of the number of non-missing genotypes for that individual. This is a much less precise estimate of parental relatedness, as $F_{\text{homo}}$ is a single-point measure which captures all genotyped homozygous loci, not just those located in long ROH. Thus it reflects not only recent parental relatedness but also more ancient aspects of population history, such as population isolation and bottlenecks.
The purpose of the first part of the analysis was to explore the association between height and homozygosity, as measured in different ways. First, we estimated the association between height and FRoH, adjusting for age, sex and (in sample sets including related individuals) genomic kinship (Table 2, Figure S1). We found evidence for a small but strongly significant ($p=1.23\times10^{-11}$) inverse association between FRoH and height. This association was significant in nine of the twenty-one sample sets in this study. In nine further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FRoH and height. In none of the sample sets was there a significant positive association between FRoH and height. An increase of 1% in FRoH was associated with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height. In none of the sample sets in the study. In eleven further sample sets, confidence intervals overlapped with zero but the direction of the effect was consistent with an inverse association between FROHLD and height.
of the sample sets was there a significant effect in the other direction. A 1% increase in \( \text{FROHLD} \) was associated with a decrease of 0.065 (SE = 0.0032) in the z-score for height (approximately 0.6 cm). Again using pedigree and \( \text{FROHLD} \) data from three separate population samples, this gave a much higher estimate of a reduction in height of between 2.8 and 3.3 cm in the offspring of first cousins compared with the offspring of unrelated parents (based on \( \text{FROHLD} \) differences of 2.8, 3.3 and 2.9 in the offspring of first cousins compared with the offspring of unrelated individuals in the MICROS, ORCADES and Irish data sets respectively).

The third analysis estimated the association between height and \( \text{Fhom} \), adjusting for age and sex (Figure S2). Again, there was evidence of a very strongly significant inverse association between \( \text{Fhom} \) and height (\( p = 1.10 \times 10^{-23} \)). The direction of effect was consistent for fourteen sample sets, significantly so for seven of these, and not significantly different from zero but of opposite sign in the final seven studies. A 1% increase in \( \text{Fhom} \) was associated with a decrease of 0.11 (SE = 0.0057) in the z-score for height (approximately 1 cm). Again using pedigree and \( \text{Fhom} \) data from three separate population samples, this gave an estimate of a reduction in height of between 2.7 and 3.3 cm in the offspring of first cousins compared with the offspring of unrelated parents (based on \( \text{Fhom} \) differences of 2.7, 3.3 and 2.7 in the offspring of first cousins compared with the offspring of unrelated individuals in the MICROS, ORCADES and Irish data sets respectively).

We explored whether the signal observed in the \( \text{Fhom} \) analysis was driven by homozygous genotypes located in long ROH, or from the more common, homozygous genotypes resulting from the chance inheritance of identical shorter haplotypes from both parents. This analysis estimated the association between height and \( \text{Fhom} \), adjusted for age, sex and \( \text{FROH} \). Again, a significant association was observed, but both the magnitude and the significance of the effect were reduced compared to the previous analysis (Table 2), suggesting that most, but not all, of the signal was coming from long ROH.

Figure 1. Three alternative measures of mean homozygosity, with 95% confidence intervals, by population sample. (A) shows mean \( \text{FROH} \) by population sample. \( \text{FROH} \) is defined as the percentage of the genotyped autosomal genome in ROH measuring at least 1.0 Mb. Mean values of \( \text{FROH} \) per population (with 95% confidence intervals) are: CROATIA-Korcula = 0.67 (0.61, 0.73); CROATIA-Split = 0.13 (0.11, 0.15); CROATIA-Vis = 0.48 (0.43, 0.53); EGCUT = 0.10 (0.09, 0.10); ERF = 0.53 (0.48, 0.58); FINRISK = 0.21 (0.20, 0.23); HBCS = 0.13 (0.11, 0.14); H2000 = 0.22 (0.22, 0.24); INGI-CARL = 0.44 (0.34, 0.54); INGI-FVG = 0.25 (0.24, 0.26); LBC1921 = 0.05 (0.03, 0.07); LBC1936 = 0.02 (0.01, 0.03); NSPHS = 2.83 (2.64, 3.02); ORCADES = 0.81 (0.75, 0.87); QIMR = 0.22 (0.21, 0.23); RS = 0.29 (0.28, 0.30); SOCCS = 0.30 (0.28, 0.32); YFS = 0.81 (0.79, 0.83). (B) shows mean \( \text{FROHLD} \) by population sample. \( \text{FROHLD} \) is defined as the percentage of the genotyped autosomal genome in ROH measuring at least 1.0 Mb, derived from a panel of independent SNPs. Mean values of \( \text{FROHLD} \) per population (with 95% confidence intervals) are: CROATIA-Korcula = 1.27 (1.18, 1.36); CROATIA-Split = 0.65 (0.59, 0.71); CROATIA-Vis = 0.94 (0.87,1.01); EGCUT = 0.56 (0.54, 0.58); ERF = 1.12 (1.04, 1.20); FINRISK = 0.79 (0.77, 0.82); HBCS = 0.63 (0.60, 0.65); H2000 = 0.84 (0.82, 0.86); INGI-CARL = 0.78 (0.65, 0.91); INGI-FVG = 1.49 (1.40, 1.58); INGI-VB = 0.76 (0.71, 0.81); LBC1921 = 0.30 (0.25, 0.35); LBC1936 = 0.26 (0.24, 0.28); MICRO = 0.93 (0.87, 0.99); NFBC1966 = 1.02 (1.00, 1.04); NSPHS = 2.83 (2.64, 3.02); ORCADES = 0.81 (0.75, 0.87); QIMR = 0.22 (0.21, 0.23); RS = 0.29 (0.28, 0.30); SOCCS = 0.30 (0.28, 0.32); YFS = 0.81 (0.79, 0.83). (C) shows mean \( \text{Fhom} \) by population sample. \( \text{Fhom} \) is defined as the percentage of genotyped autosomal SNPs that are homozygous. Mean values of \( \text{Fhom} \) per population (with 95% confidence intervals) are: CROATIA-Korcula = 65.47 (65.43, 65.51); CROATIA-Split = 65.28 (65.25, 65.31); CROATIA-Vis = 65.61 (65.58, 65.64); EGCUT = 65.69 (65.68, 65.70); ERF = 65.32 (65.29, 65.35); FINRISK = 65.25 (65.23, 65.27); HBCS = 65.13 (65.12, 65.14); H2000 = 65.24 (65.23, 65.25); INGI-CARL = 65.20 (65.14, 65.26); INGI-FVG = 65.53 (65.49, 65.57); INGI-VB = 65.18 (65.16, 65.20); LBC1921 = 65.00 (64.97, 65.03); LBC1936 = 65.00 (64.99, 65.01); MICRO = 65.26 (65.23, 65.29); NFBC1966 = 65.27 (65.26, 65.28); NSPHS = 66.09 (66.01, 66.17); ORCADES = 65.37 (65.34, 65.40); QIMR = 64.75 (64.74, 64.76); RS = 65.00 (64.99, 65.01); SOCCS = 64.97 (64.95, 64.99); YFS = 65.26 (65.25, 65.27).

doi:10.1371/journal.pgen.1002655.g001

Inbreeding Depression on Height
Although these results were highly significant, there was also a high degree of heterogeneity across population samples. Some further analyses were performed to explore the source of this heterogeneity. Three of the twenty-one study samples (Carlantino [INGI-CARL], Lothian Birth Cohort 1936 [LBC1936] and Val Borbera [INGI-VB]) consistently showed a (non-significant) positive association between genome-wide homozygosity and height. In the LBC1936 and INGI-VB cohorts, the parameter estimate was positive for all three measures. In INGI-CARL, the parameter estimate was positive for \(F_{Roh} \) and \(F_{Rohld} \); however, the maximum likelihood method used to find the parameter estimate failed to converge for the \(F_{hom} \) analysis. Excluding these three cohorts from the \(F_{Rohld} \) meta-analysis reduced heterogeneity considerably, whilst not eliminating it completely (p-value for heterogeneity = 0.01).

Removing these cohorts only slightly reduced heterogeneity in the \(F_{hom} \) (p-value for heterogeneity = 6.6 \times 10^{-16}) and \(F_{Roh} \) meta-analyses (p-value for heterogeneity = 1.3 \times 10^{-16}). For both these measures, other outliers also contributed to the heterogeneity. In the case of \(F_{Roh} \) the Rotterdam Study (RS) showed a non-significant positive association with height. Four additional cohorts showed a non-significant positive association between \(F_{hom} \) and height (EGCUT, CROATIA-Korčula, Queensland Institute of Medical Research [QIMR] and RS).

To summarise, these results provide evidence of a highly significant inverse association between genome-wide homozygosity and height, regardless of which homozygosity estimate was used. The weakest result was for \(F_{Roh} \). The effect estimate for this analysis was lower than those for the other 2 homozygosity measures. The most heterogeneous result was for \(F_{hom} \). The \(F_{hom} \) analysis was similar to \(F_{Rohld} \) in terms of effect size and significance; however, when \(F_{Roh} \) was included in the \(F_{hom} \) model, although the association remained significant, the effect size fell, the p-value increased and heterogeneity increased. This suggests that the effect was being driven mainly by longer ROH which are more effectively captured by \(F_{Rohld} \). It is important not to overstate this, however: even after controlling for \(F_{Roh} \), there is a significant, although highly heterogeneous inverse association between \(F_{hom} \) and height, which suggests that a signal is also coming from homozygous genotypes that are not found in the long ROH characteristic of parental relatedness (Table 2). Furthermore, no correlation was observed between sample mean \(F_{Rohld} \) and effect size (\(r = 0.03\)).

Correlation between these two measures would be expected if the observed effect was entirely attributable to parental relatedness of recent origin. Nevertheless, the most significant and least heterogeneous result was seen with \(F_{Rohld} \). Furthermore, a moderate negative correlation was observed between average \(F_{Rohld} \) and the standard error of the effect estimate (\(r = -0.4\)), suggesting that the higher the level of parental relatedness present in the sample, the greater the precision of the effect estimate. This is because mean \(F_{Rohld} \) is related to its standard deviation (higher mean, higher variance) and it is the variance in \(F_{Rohld} \) that determines the standard error of the estimate of the regression coefficient (i.e. higher variance, lower standard error). For these reasons, it was decided to use \(F_{Rohld} \) in further analyses to explore possible confounding factors.

All analyses were adjusted for age but, because the mean age of most of the population samples in this study was over 50 years at the time of genotyping, it was important to undertake additional checks to ensure that the observed effect was not confounded by the effects of osteoporotic, age-related shrinking. We used the Northern Finland Birth Cohort 1966 (NFBC1966), where all subjects were under 40 at the time of measurement. In this cohort, there was a significant inverse association between \(F_{Rohld} \) and height, with a 1% increase in \(F_{Rohld} \) associated with a decrease of 0.13 in the z-score for height (95% confidence interval = −0.16, −0.10). This is equivalent to a reduction in height of 5.3 cm (95% confidence interval = −4.1, −6.6) in the offspring of first cousins compared with the offspring of unrelated parents, a stronger effect than observed in the meta-analysis of the full sample. We also repeated the \(F_{Rohld} \) analysis for a subset of individuals aged under 40 years of age (15 cohorts, \(n = 9909\)) and the relationship remained significant, although the effect size was much smaller (1% increase in \(F_{Rohld} \) associated with a decrease of 0.009 in the z-score for height (95% confidence interval = −0.013, −0.0049; \(p = 2.15 \times 10^{-10}\)). This is equivalent to a reduction in height of 0.4 cm (95% confidence interval = −0.2, −0.5) in the offspring of first cousins compared with the offspring of unrelated parents.

The final stage in this analysis was to investigate possible confounding by socio-economic status (SES) of the observed association between genome-wide homozygosity and reduced height. Four of the 21 cohorts (Erasmus Rucphen Family Study [ERF], MICROS, NSPHS and QIMR) did not collect data on SES and so were excluded from further analyses. SOCCS estimated SES using a composite measure of deprivation based on residential address; however, because this was an area- rather than an individual-level estimate and because only one other cohort (ORCADES) used this measure, SOCCS was also excluded from analyses of SES. Eleven cohorts recorded an ordinal measure of educational attainment (CROATIA-Korčula, CROATIA-Split, CROATIA-Vis, EGCUT, the National FINRISK Study [FINRISK], the Health2000 Survey [H2000], FVG-Generic Park [INGI-FVG], INGI-VB, NFBC1966, ORCADES and RS). Seven cohorts provided an ordinal measure of occupational status (EGCUT, Helsinki Birth Cohort Study [HBCS], INGI-CARL, INGI-FVG, INGI-VB, the Lothian Birth Cohort 1921 [LBC1921], LBC1936 and the Young Finns Study [YFS]); however, the maximum likelihood method used to find the parameter estimate failed to converge for INGI-FVG so this cohort was excluded from the occupational status analysis.

### Table 2. Meta-analysis of the association between height and genome-wide homozygosity, adjusted for age and sex only.

| Homozygosity measure | Number of participants | Effect size (z-score units) | 95% Confidence Interval | p-value | p-value (heterogeneity) |
|----------------------|------------------------|-----------------------------|------------------------|---------|------------------------|
| \(F_{Roh} \)         | 35,808                 | −0.012                      | −0.015, −0.008         | \(1.23 \times 10^{-11}\) | \(4.7 \times 10^{-16}\) |
| \(F_{Rohld} \)       | 35,808                 | 0.005                       | −0.071, −0.058         | \(1.40 \times 10^{-9}\) | \(3.7 \times 10^{-7}\) |
| \(F_{hom} \)         | 35,378                 | −0.11                       | −0.12, −0.10           | \(1.10 \times 10^{-3}\) | \(8.7 \times 10^{-19}\) |
| \(F_{hom, adj} F_{Roh} \) | 35,378               | −0.023                      | −0.030, −0.016         | \(5.36 \times 10^{-11}\) | \(1.5 \times 10^{-12}\) |

doi:10.1371/journal.pgen.1002655.t002
conducted four meta-analyses to investigate whether educational attainment or occupational status confounded the association between genome-wide homozygosity and height (i.e. inbreeding depression) using three alternative estimates of genomic homozygosity, with each method capturing a somewhat different aspect of this phenomenon. Whereas all three measures are strongly correlated, there are also important differences, particularly between \( F_{\text{hom}} \) and both \( F_{\text{ROH}} \) measures. For example, whereas the Estonian sample (EGCUT) had the second highest mean value for \( F_{\text{hom}} \), it had one of the lowest mean values for \( F_{\text{ROH}} \). There are several possible explanations for this. Firstly, it may be suggestive of a small, isolated population deep in the past but with a larger population size and low levels of parental relatedness in recent generations. Secondly, ascertainment bias in the selection of SNPs may also influence these patterns, as markers present in the HumanHap300 panel are more likely to be heterozygous in NW Europeans [37]. Thirdly, it may be that the level of parental relatedness in the sample is lower than that in the population.

The strongest association between genome-wide homozygosity and reduced height was observed using \( F_{\text{ROH}} \), a measure which estimates homozygosity attributable to recent parental relatedness. There is, however, an important caveat: a significant association was also observed between reduced height and \( F_{\text{hom}} \), controlled for \( F_{\text{ROH}} \), suggesting that homozygous genotypes not located in the long ROH characteristic of recent parental relatedness are also important. We estimated that the increased genome-wide homozygosity that is characteristic of consanguinity results in a reduction of up to 3 cm in the height of the offspring of first cousins compared with the offspring of unrelated parents. Using \( F_{\text{ROH}} \), we then expanded the model to explore possible confounding factors. Firstly, we investigated the possible confounding effects of age-related shrinking. Adult height is the combined effect of growth during childhood and adolescence and loss of height during ageing [11]. There is a powerful age-cohort effect on homozygosity [38] (McQuillan and Wilson unpublished): the rapid pace of urbanisation and population mobility that we have witnessed over the past century has resulted in an observable decrease in homozygosity in younger, compared with older age cohorts. Reduced height is also associated with age, both as a cohort effect reflecting improvements in nutrition and living standards, and because as part of the natural process of ageing, adults lose height as they age due to osteoporotic changes. This process, which is particularly marked in women, may start as young as age 40 [39], with the effects accelerating with age [40]. All analyses were adjusted for age, but as an additional test, we restricted the samples to individuals aged <40. The NFBC1966 sample set provided a further check, as all subjects were aged 31 years at the time of measurement. The inverse association between \( F_{\text{ROH}} \) and height remained in both these analyses, suggesting that confounding as a result of the osteoporotic effects of ageing was not a major factor in these samples. The NFBC1966 analysis also suggests that the relationship between genome-wide homozygosity and height is not confounded by the simultaneous...
improvements in nutrition and living standards over the last century.

Secondly, we assessed possible confounding by socio-economic status. The association between low childhood SES and reduced adult stature is well established, with the likely mechanism being poor nutrition during childhood [6], although shared genetic factors cannot be excluded. There is no direct evidence on the association between genome-wide homozygosity and SES; however there is a substantial literature on the association between consanguinity, or kin marriage, and SES, albeit not in European populations, where kin marriage is rare. In South and West Asian Muslim populations, where kin marriage is customary, many studies have reported an inverse association between consanguinity and women’s educational status [41], although the picture is less clear-cut in men [42]. In a large post-World War Two study of the children of consangunineous parents living in the Japanese cities of Hiroshima and Nagasaki, which used a multi-dimensional SES score, Schull and Neel found a small negative correlation between consanguinity and SES [43]. A later Japanese study also found evidence of confounding by SES, although the direction of the effect was opposite depending on the urban or rural background of the subjects [33]. SES can be estimated in a variety of different ways: the measures available to us here were educational attainment and occupational status. We grouped all the cohorts with ordinal measures of educational attainment together and performed two meta-analyses: one adjusting for age, sex and genomic kinship only and the other adjusting for age, sex, genomic kinship and educational attainment. We compared the two meta-analyses to assess the effect of educational attainment as a possible confounder. We repeated this process for the cohorts with ordinal measures of occupational status. The inclusion of either SES measure in the model made very little difference to the results. We therefore found no strong evidence for confounding by SES, although the limited data available on SES mean that confounding by SES cannot be ruled out entirely.

While we did not have access to raw intensity data with which to call hemizygous deletions, which can masquerade as ROH, two different studies give us confidence that such copy number variation will only have a very minor effect on our results. First, in the ORCADES population, removing ROH which overlapped with deletions resulted in only a 0.3% reduction in the sum length of ROH across the cohort [36]. Second, the median length of these deletions was ~10 kb in a dataset of >7,000 European-heritage subjects, whereas the median length of ROH in the same studies was ~2,000 kb, showing that the vast majority of deletions will be smaller than the ROH under study here [44]. However, we note that an increased burden of deletions has recently been associated with short stature [45].

Our results are consistent with those of Macgregor and colleagues, who found a significant inverse association between height and both the inbreeding coefficient derived from genealogical data ($F_{ped}$) ($p = 0.03$; $n = 60$) and genome-wide homozygosity ($p = 0.02$; $n = 593$) in the extreme isolate population of Norfolk Island [34]. The probable reason that they were able to see an effect with such small samples is that they observed much higher levels of parental relatedness than are present in most of the samples used in the present study, therefore the study had greater power to detect an effect. Over one quarter (26%) of their total sample had $F_{ped}>0$, with mean $F_{ped} = 0.044$. This contrasts with, for example, only 10% of the ORCADES sample having $F_{ped}>0$, with mean $F_{ped} = 0.01$ using pedigrees of a similar depth (unpublished data). Although comparable pedigree data are not available for all samples, it is probable that, with the possible exception of NSPIS, all the samples in the present study have lower levels of $F_{ped}$ and genome-wide homozygosity and thus lower power to detect an association with height than is the case in the Norfolk Island sample of descendents of the Bounty mutineers. Cultural attitudes to consanguinity are at best ambivalent in Europe, so marriage between first cousins is rare, even in the nine isolated population samples in our consortium, where inflated levels of parental relatedness are predicted simply as a function of population size and endogamy.

The present study’s analyses provide strong evidence for an association between genomic homozygosity and reduced height; however, there is also strong evidence of heterogeneity. Although we did not find a significant positive association between $F_{ROHLD}$ and height in any sample, there was a small number of non-significant positive associations and overall there was considerable variation in the magnitude of the observed effects among population samples. One possible explanation for this is that the observed effects are found only in individuals whose parents are closely related (e.g. as first cousins). If this were the case, however, the strongest effects would be observed in the samples with the highest levels of parental relatedness. In fact, we found no correlation between mean sample $F_{ROHLD}$ and effect size. We also found evidence of an association after controlling for parental relatedness, suggesting that homozygous genotypes not resulting from recent parental relatedness also contribute to the observed association. The data do not, then, support the hypothesis that the more inbreeding there is in the sample, the stronger the observed effect. We did, however, find a moderate negative correlation between the mean sample $F_{ROHLD}$ and the SE of the $F_{ROHLD}$ effect estimate, which suggests that the more inbreeding there is in the sample the greater the power to detect an effect and therefore the more precise the estimate of the effect.

One puzzling result of this study was the discrepancy in the results of the meta-analyses of $F_{ROH}$ and $F_{ROHLD}$. The difference in ROH length threshold may contribute to this discrepancy. The 1.5 Mb threshold for $F_{ROH}$ was chosen on the basis of an empirical analysis of several European-heritage populations [36].

| Covariates | N samples | N subjects | Effect size | 95% Confidence Interval | p-value (heterogeneity) |
|------------|-----------|------------|-------------|------------------------|------------------------|
| Age, sex, $F_{ROHLD}$ | 11 | 22,430 | −0.067 | −0.083, −0.051 | 6.3×10^{-7} |
| Age, sex, $F_{ROHLD}$, EA | 11 | 22,085 | 0.068 | −0.082, −0.053 | 5.2×10^{-20} |
| Age, sex, $F_{ROHLD}$, OS | 7 | 10,161 | −0.0063 | −0.037, 0.024 | 0.69 |
| Age, sex, $F_{ROHLD}$, OS | 7 | 8,459 | −0.0063 | 0.073 |

SES variables are educational attainment (EA) and occupational status (OS).
doi:10.1371/journal.pgen.1002655.t003

Table 3. Meta-analysis assessing potential confounding of SES variables on the association between $F_{ROHLD}$ and height.
Inbreeding Depression on Height

All individuals in all samples observed in this study, which also used the Illumina Hap300 SNP array, had ROH < 1.5 Mb. ROH longer than this were more common in the offspring of related parents, although still present in most offspring of unrelated parents. With the benefit of hindsight, a longer and thus more stringent ROH length threshold may have been preferable, in terms of differentiating ROH resulting from close parental relatedness originating in recent generations from what might be termed population homogeneity resulting from population isolation deeper in the past. In contrast, the FROHLD measure does not detect ROH arising from common ancient haplotypes in the population because SNPs in LD are removed before the analysis. Any ROH detected using FROHLD are the result of parental relatedness of recent origin. For FROHLD, the aim is to maximize the ROH that can be detected by setting a minimum length threshold which is as low as possible. ROH are identified by observing a string of contiguous homozygous genotypes. The greater the number of contiguous homozygous genotypes, the stronger the probability that what is observed is a true ROH (i.e., a segment where the entire stretch of unobserved intervening DNA is also homozygous), rather than just a chance observation. Because of the reduced number of SNPs, and thus reduced SNP density, in the LD-pruned SNP panels used for the FROHLD analysis, detection of ROH shorter than 1 Mb becomes unreliable: hence 1 Mb was used as the threshold.

The purpose of carrying out this analysis was to investigate possible genome-wide recessive effects on height. These results are important because by showing an association with genome-wide homozygosity rather than specific individual SNPs, we provide evidence that there is a polygenic recessive component to the genetic architecture of height: i.e., that the observed reductions in height associated with genome-wide homozygosity result from the combined effects of many recessive alleles of individually small effect size, located across the genome. The proportion of the phenotypic variance explained by FROHLD was very variable across cohorts, but the average was 0.4%. Secondly, by demonstrating that the strongest signal comes from the long ROH characteristic of parental relatedness, we provide evidence that the observed effect is primarily the result of rare, rather than common, recessive alleles. Short ROH (measuring up to 2 Mb) are a common feature of all our genomes [36] and their locations are remarkably consistent across different populations, at least within Europe [46]. In contrast, the longer ROH characteristic of parental relatedness are randomly distributed across the genome [36], can be composed of common or rare haplotypes, and as such are predicted to be enriched for rare recessive variants. Our suggestion that it is rare, rather than common, recessive variants that are driving the observed effect is consistent both with theoretical expectations [47] and with empirical data. Two recent studies found evidence that functional regions of the genome (i.e., protein coding regions or regions governing gene expression) are enriched for rare genetic variants. Zhu et al. (2011) conclude that rare, at least moderately harmful, variants constitute the majority of the genetic variation responsible for complex traits. This study provides further evidence for the concept of the “rare disease common variant” hypothesis. The FOHLD analysis is designed to detect ROH characteristic of parental relatedness that are randomly distributed across the genome, whereas the FROHLD analysis is designed to detect ROH characteristic of parental relatedness that are concentrated in regions with high homozygosity. The results of the two studies are consistent with each other, and provide further evidence for the concept of the “rare disease common variant” hypothesis.
human functional variation [48]. Li et al. (2010) found that non-synonymous coding SNPs were much rarer than synonymous coding SNPs, suggesting that these SNPs have been subject to purifying selection, which in turn suggests that they are deleterious. They found that this pattern was stronger in the X-chromosome than in the autosomes, suggesting that most rare deleterious SNPs are recessive [49].

These findings are also important because, if there is a polygenic, rare, recessive component to the genetic architecture of height, this might also be the case for disease-associated QT of biomedical importance, such as blood pressure and lipid levels. Indeed this is more likely, if these traits are associated with fitness. A high dominance variance has been reported in systolic blood pressure (SBP) and LDL cholesterol in the Hutterites [50]. For this reason, there is a theoretical expectation that these QT will be influenced by genome-wide homozygosity. There have been many empirical studies over the years which have explored this recessive component to the genetic architecture of blood pressure and LDL cholesterol; however until genome-wide scan data became routinely affordable, this could only be investigated indirectly using inbreeding coefficients derived from genealogical data ($F_{ped}$). Such measures are highly error-prone and cannot account for stochastic variation in the inheritance process. Nevertheless, various studies have found evidence of a significant positive association between blood pressure and $F_{ped}$ [51,52,53,54,55] although other similar studies found no such evidence [56,57]. One small study by Campbell and colleagues replicated these findings using a genomic measure of homozygosity derived from microsatellite data [32]. Blood pressure in this Croatian island isolate population was significantly ($p<0.05$) higher in the offspring of consanguineous parents compared with the offspring of unrelated parents. Similarly, there is some evidence of a positive association between total cholesterol and $F_{ped}$ [58] and between low density lipoprotein cholesterol (LDL) and $F_{ped}$ [59] and of a negative association between high density lipoprotein (HDL) and $F_{ped}$ [60], although other studies have come up with more ambiguous results [28,55]. The study by Campbell and colleagues found significant positive associations between both total cholesterol and LDL cholesterol and homozygosity, using a panel of microsatellite markers. All these, however, were very small studies. The ROHgen consortium is well placed to investigate these questions thoroughly: we have well-developed methodology applicable to any number of different QT.

Materials and Methods

Ethics Statement

Each study had ethical approval for genetic research into the basis of complex traits, approved by the appropriate committees in each country. All participants provided written informed consent. As analyses were performed locally by cohort analysts, no data were shared across national boundaries.

Study Participants

This meta-analysis combined data from 21 European or European-heritage population samples: The Estonian Genome Centre University of Tartu (EGCUT), the Erasmus Rucphen Family Study (ERF), the National FINRISK Study (FINRISK) (genotyped samples from 1997, 2002 and 2007 study years), the Health 2000 Survey (HE2000), the Helsinki Birth Cohort (HBCS), the Lothian Birth Cohort 1921 (LBC1921), the Lothian Birth Cohort 1936 (LBC1936) the Carlantino Project (INGI-CARL), Friuli-Venezia-Giulia-Gene Park (INGI-FVG), Korčula (Croatia-Korčula), Micro-Isolates in South Tyrol (MICROS), the Northern Finland 1966 Birth Cohort (NFBC1966), the Northern Sweden Population Health Study (NSPHS), the Orkney Complex Disease Study (ORCADES), Queensland Institute of Medical Research (QIMR), the Rotterdam Study (RS), the Study of Colorectal Cancer in Scotland (SOCCS), Split (Croatia-Split), Val Borbera (INGI-VB), Vis (Croatia-Vis) and the Young Finns Study (YFS). Most ($n=16$) were population-based samples, 4 were birth cohorts and 1 was a case-control sample. Five study populations were Finnish, 4 were Scottish, 4 were Italian, 3 were Croatian, 2 were Dutch, 1 was Estonian, 1 was Swedish and 1 was Australian of NW European heritage. Most of the samples were drawn from genetically isolated populations or populations with increased homozygosity, such as the Finns. The total number of participants was 35,808. All studies were carried out after the appropriate local ethical approval had been obtained. All participants provided written informed consent. Full sample details are given in Table S1.

Measurement of Height

In all studies apart from SOCCS, height was measured by trained personnel using a stadiometer. SOCCS participants provided self-reported measurements of height. This was validated by measuring height in a subset of the sample by trained personnel using a stadiometer. There was a high concordance between the two measures.

Genotyping

All genotyping was performed on the Illumina platform but using four different SNP panels. Seven samples were genotyped using the Illumina HumanHap 300 panel, six using the Illumina HumanHap 370 Duo/Quad panels, five using the Illumina Human 610 Quad panel, one using the Illumina Human 670 Quad panel and one using both the 370 and 610 panels. In order to harmonise the data across samples, SNPs present in the HumanHap 300 panel were extracted and the analysis was conducted using these SNPs only. Quality control procedures were performed on each sample separately, with the minimum requirements as follows. Individuals with more than 5% missing genotypes were excluded. SNPs missing in more than 10% of samples were excluded, as were SNPs failing the Hardy-Weinberg equilibrium test at $p<0.0001$ and SNPs with minor allele frequency (MAF) <$0.01$.

Measures of Genome-Wide Homozygosity

These were detected using the Runs of homozygosity routine in plink [61,62]. This slides a moving window of 5000 kb (minimum 50 SNPs) across the genome to detect long contiguous runs of homozygous genotypes. An occasional genotyping error occurring in an otherwise unbroken homozygous segment could result in the underestimation of ROH lengths. To address this, the routine allows one heterozygous and five missing calls per window.

$F_{ROH}$ - ROH were defined as runs of at least 25 consecutive homozygous SNPs spanning at least 1500 kb, with less than a 100 kb gap between adjacent SNPs and a density of SNP coverage within the ROH of no more than 20 kb/SNP. For each individual, an F statistic termed $F_{ROH}$ [36] was derived by summing the lengths of all ROH longer than 1500 kb and expressing this as a percentage of the typed autosomal genome (i.e. the sum of the length of all the autosomes from the first to the last SNP, excluding the centromeres). 1500 kb was chosen as the
minimum length of ROH because observational studies in European populations have shown that whereas all individuals have ROH shorter than 1500 kb, ROH longer than this are more likely to be the result of parental relatedness [36]. We have shown previously that this measure is strongly correlated \( r = 0.86 \) with pedigree-derived inbreeding coefficients [36].

\( F_{\text{ROHLD}} \) - An alternative approach to deriving an inbreeding coefficient from ROH is to start by pruning the SNP panel of SNPs in strong linkage disequilibrium (LD), in order to remove ROH that are very common due to the high frequency of ancestral haplotypes. SNP panels were pruned using the pairwise option in plink [61]. At each point, it calculates LD between each pair of SNPs in a window of 50 SNPs and removes one of each pair if LD exceeds the user-defined limit (set here at \( r^2 = 0.1 \)). ROH parameters were adjusted to reflect the reduced number of SNPs. The minimum number of consecutive homozygous SNPs constituting a ROH was set at 12 (probability of occurring by chance \( p < 0.005 \) in all samples). The minimum length of ROH was set at 1000 kb, with no more than 250 kb gap between adjacent SNPs and a density of SNP coverage within the ROH of no more than 100 kb/SNP. Individual \( F_{\text{ROHLD}} \) statistics were then calculated as described above. This approach yields a more stringent estimate of parental relatedness, as it removes all ROH that are there simply because of parental sharing of long haplotypes that are common in the population. ROH consisting of independent SNPs will be of recent origin and will thus be enriched for rarer haplotypes. Again, this is highly correlated with the pedigree-derived inbreeding coefficient \( (r = 0.82 \) in a subset of 241 subjects from the ORCADES sample with complete pedigree information available to five ancestral generations).

**Observed homozygosity** \( (F_{\text{hum}}) \). This is defined as the number of observed homozygous genotypes per individual, expressed as a percentage of the number of non-missing genotypes for that individual. This measure is less strongly correlated with pedigree inbreeding coefficients than the above \( (r = 0.76 \) [36]), as it counts all homozygous genotypes and not simply those found in long ROH arising from recent pedigree loops.

**Statistical Analysis**

All tests were two sided and a \( p \)-value threshold of 0.05 was used. In order to account for differences in mean height among population samples, all height measures are expressed as z-scores. Because genetically isolated populations are characterised by high levels of relatedness between individuals, measures of height are not independent and therefore conventional regression techniques are not appropriate. The CROATIA-Korčula, CROATIA-Split, CROATIA-Vis, ERF, FINRISK, HBCS, H2000, INGI-CARL, INGI-FVG, INGI-VB MICROs, NFBc1966, NSPhS, ORCADES and YFS samples were therefore analysed using a linear mixed polygenic model in GenABEL. This programme maximises the likelihood of the data under the polygenic model with specified covariates. It reports twice the negative maximum likelihood estimates and the inverse of the variance-covariance matrix at the point of maximum likelihood [63,64,65]. The z-score for height was analysed with age, sex, genome-wide homozygosity measure and either educational attainment or occupational status fitted as fixed effects. This model also fits a genomic kinship matrix, which estimates pairwise relatedness, derived on the basis of identical by state (IBS) sharing, weighted by allele frequency, so that a pair of individuals sharing a rare allele is estimated to be more closely related than a pair sharing a common allele. All other samples consist of unrelated individuals, so data were analysed in SPSS using simple linear regression, with age, sex, genome-wide homozygosity measure and either educational attainment or occupational status as covariates. Before embarking on analysis of the SOCCS data, the sample was analysed using binary logistic regression to check that height is not associated with colorectal cancer status. There was no association between height and colorectal cancer, so cases and controls were analysed as a single sample.

**Meta-Analysis**

Results were combined in a meta-analysis using the inverse variance method to combine effect size estimates from each sample [63]. This weights each sample estimate by the inverse of the squared standard error of the regression coefficient, so that the smaller the standard error of the study, the greater the contribution it makes to the pooled regression coefficient.

**Estimation of the Reduction in Height Resulting from Increased Homozygosity in the Offspring of First Cousins Compared with the Offspring of Unrelated Individuals**

In order to standardise across the different population samples in this study, we converted height measurements into z-scores. The results of each meta-analysis report a pooled estimate of the change in this z-score associated with a 1% increase in genomic homozygosity. In order to make this easier to interpret, we express this in the text as the difference in height between the offspring of first cousins and the offspring of unrelated parents. The first step in this analysis was to estimate the difference in observed genomic homozygosity between the offspring of first cousins and the offspring of unrelated parents (a more realistic approach than using the theoretical predictions of \( F_{\text{ped}} = 0.0625 \) and 0). For each measure of genomic homozygosity we estimated this difference separately in 3 different populations where genealogical and genomic data were available for the reliable identification of the offspring of first cousins. In each population group and for each measure of genomic homozygosity, we estimated the mean difference between the offspring of first cousins and the offspring of unrelated parents. We multiplied this by the effect size estimate from the regression meta-analysis to give a z-score estimate for the reduction in height in the offspring of first cousins compared with the offspring of unrelated individuals. To convert each of these z-scores into cm, we then multiplied them by an estimate of the SD for height across the whole sample, derived by taking the SD for each sample in turn and weighting it by sample size. Two of the three populations used for this analysis were part of the main study (ORCADES and MICROS). The third was a small Irish sample, consisting of members of both settled and traveller communities in Ireland (unpublished data, JF Wilson and GL Cavalleri). We repeated this analysis separately in these three populations, partly because of the very small number of first cousin offspring in any single sample in our study and partly to ensure that the observed difference in homozygosity was not simply an artefact of one particular population sample.

**Supporting Information**

**Figure S1** Forest plot of the effect of \( F_{\text{ROH}} \) on height. Results of a meta-analysis of the association between \( F_{\text{ROH}} \) and height are shown for twenty-one population samples. The model was adjusted for age and sex in all samples. Additionally, it was adjusted for genomic kinship in samples with pairs of related individuals (CROATIA-Korčula, CROATIA-Split, CROATIA-Vis, ERF, FINRISK, HBCS, H2000, INGI-CARL, INGI-FVG, INGI-VB MICROs, NFBc1966, NSPhS, ORCADES and YFS). The plot shows estimated effect sizes (solid squares) for each population, with 95% confidence intervals (horizontal lines). Each sample estimate is weighted by the inverse of the squared
standard error of the regression coefficient, so that the smaller the standard error of the study, the greater the contribution it makes to the pooled regression coefficient. The area of the solid squares is proportional to the weighting given to each study in the meta-analysis. Effect sizes in z-score units (with 95% confidence intervals) are: CROATIA-Korcula = -0.03 (-0.06, -0.003); CROATIA-Split = -0.03 (-0.09, 0.00006); CROATIA-Vis = -0.03 (-0.07, 0.007); EG CUT = -0.04 (-0.3, 0.2); ERF = -0.09 (-0.3, 0.3); FINRISK = -0.09 (-0.2, -0.01); HBGS = -0.05 (-0.2, 0.1); H2000 = -0.16 (-0.2, -0.1); INGICARL = 0.01 (-0.03, 0.05); INGIFVG = -0.03 (-0.05, -0.005); INGIVB = 0.001 (-0.02, 0.02); LBC1921 = -0.08 (-0.2, 0.03); LBC1936 = -0.07 (-0.1, 0.2); MICROSG = -0.05 (-0.02, -0.003); NFBC1966 = -0.08 (-0.1, -0.05); NSPHS = -0.02 (-0.04, -0.003); ORC ADES = -0.02 (-0.06, 0.02); QIMR = -0.06 (-0.2, 0.09); RS = 0.003 (-0.06, 0.06); SOCCS = -0.08 (-0.2, 0.05); YFS = -0.05 (-0.1, -0.002).

(TIF)

Figure S2 Forest plot of the effect of Fhom on height. Results of a meta-analysis of the association between Fhom and height are shown.

| Study | Effect Size (95% CI) |
|-------|---------------------|
| ASH 2000 | -0.02 (-0.1, 0.0) |
| CROATIA-Korcula | -0.03 (-0.06, -0.003) |
| CROATIA-Split | -0.03 (-0.09, 0.00006) |
| CROATIA-Vis | -0.03 (-0.07, 0.007) |
| EG CUTC | -0.04 (-0.3, 0.2) |
| ERF | -0.09 (-0.3, 0.3) |
| FINRISK | -0.09 (-0.2, -0.01) |
| HBGS | -0.05 (-0.2, 0.1) |
| H2000 | -0.16 (-0.2, -0.1) |
| INGICARL | 0.01 (-0.03, 0.05) |
| INGIFVG | -0.03 (-0.05, -0.005) |
| INGIVB | 0.001 (-0.02, 0.02) |
| LBC1921 | -0.08 (-0.2, 0.03) |
| LBC1936 | -0.07 (-0.1, 0.2) |
| MICROSG | -0.05 (-0.02, -0.003) |
| NFBC1966 | -0.08 (-0.1, -0.05) |
| NSPHS | -0.02 (-0.04, -0.003) |
| ORC ADES | -0.02 (-0.06, 0.02) |
| QIMR | -0.06 (-0.2, 0.09) |
| RS | 0.003 (-0.06, 0.06) |
| SOCCS | -0.08 (-0.2, 0.05) |
| YFS | -0.05 (-0.1, -0.002) |

(TIF)

Table S1 Details of genotyping, QC, data analysis and sample characteristics by cohort.

(XLS)

Acknowledgments

The authors would like to acknowledge the contributions of Jo Graham and Gianpietro Cavalleri and the following:

CROATIA- Korcula: the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh, and the people of Korcula.
CROATIA-Split: the recruitment team from the Croatian Centre for Global Health, University of Split, the administrative teams in Croatia and Edinburgh, and the people of Split.
CROATIA-Vis: the recruitment team in Vis (including those from the Institute of Anthropological Research in Zagreb), the administrative teams in Croatia and Edinburgh, and the people of Vis. CROATIA-Vis genotyping was performed in the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, Scotland.

EGCUT: EG CUTC and Estonian Biocentre personnel, especially Ms. M. Hass and Mr V. Soold. EG CUTC data analysis was carried out in part in the High Performance Computing Centre of University of Tartu.
ERF: all patients and their relatives, general practitioners, and neurologists; P. Veraart for help with genealogy, Jeanette Vergeer for supervision of the laboratory work; P. Snijders for his help in data collection; Internationale Stichting Alzheimer Onderzoek (ISAO) and Biounmuchiing Netherlands.
FINRISK: the study participants.
HBCS: study participants and all those involved in the Helsinki Birth Cohort Study.
HEALTH2000: the study participants.
INGI-CARLI: the Carlangtino population.
INGI-FVG: the local population.
INGI-VB: the inhabitants of the Val Borbera, the local administrators, the ASL-22, Novi Ligure (AL); Clara Camaschella (Vita e Salute University, HSR); Federico Calligaris-Cappio (Oncology-HSR) and the internal medicine MDs of the San Raffaele Hospital; Maria Rosa Biglieri and Diego Sballi for their contribution to clinical data collection; and Fiammetta Viganò for technical support.
LBC1921 and LBC1936: the Lothian Birth Cohort 1921 and 1936 participants, the research associates, the study secretary, the Scottish Council for Research in Education, and the research nurses at the Wellcome Trust Clinical Research Facility.
MICROS: the primary care practitioners Raffaella Stocker, Stefan Waldner, Toni Pizzeco, Josef Planger, Ugo Marcadent, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine).
NSPHS: the participants in Karesuando parish.
ORC ADES: Lorraine Anderson and the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.
QIMR: the study participants.
RS: the study participants; the staff from the Rotterdam Study and the participating general practitioners and pharmacists; Pascal Arc, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters for their help in creating the GWAS database.
SOCCS: the COGS and SOCCS administrative teams; R. Cetnarski yj and research nurse team: all who recruited to the studies; the Wellcome Trust Clinical Research Facility for sample preparation. In particular, we gratefully acknowledge the participation of all subjects from across Scotland in the COGS and COGS cohort.
YFS: Irina Läsnien and Ville Aalto for expert technical assistance in data management and statistical analysis.

Author Contributions

Analyzed the data: R McQuillan, N Eklund, N Pirastu, BP McEvoy, M Kuningas, T Eko, C Torre, G Davies, L-P Lytyiäkinen, K Kristiansson, M Kirin, M Gögele, V Vitati, Y Aluchenko, C Hayward, A Johansson, W IgI, N Amini, LM Lopez, K Estrada, C Masciullo, G Pisis, T Lhetimaï, J Yang, F Rivadeneira, PM Vischer, OT Raitakari, T Corre, A Teresa, L Milan, M Kals, K Fischer. Wrote the paper: R McQuillan, JF Wilson. Conceived and designed the experiments: D Porteous, K Fischer, A Metspalu. Established and managed the population resources: A S Havulinna, C Hayward, A Johansson, M Bozan, So Ulivi, V Boraska, W IgI, SH Wild, L Zgaga, E Theodoratou, O Polaïek, J Lahti, L Laatikainen, I Prokopenko, J Viikari, AA Hicks, M Kähönen, E Wideña, V Salomaa, T Lhetimaï, H Tiemeier, P Rivadeneira, PM Vischer, OT Raitakari, T Corre, A Teresa, L Milan, M Kals, K Fischer. Participated in the laboratory work: P. Snijders for his help in data collection; Internationale Stichting Alzheimer Onderzoek (ISAO) and Groep Alzheimer Nederland (GAN) for funding.

Czech Science Foundation: V 13-00819S, V 13-00818S, V 13-00819S; the Czech Ministry of Health: Research Project No. IN3/13, OP V蝎/12; project of the Hospital of Silandro (Department of Laboratory Medicine).

This project has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 223070-2 (ADAI) and No. 223071-2 (ADAM) and the Special Research Fund of the University of Leuven (OT/08/071), the Special Research Fund of the University of Antwerp (BOF 010020_09, BOF 010020_12), the Fonds voor Meerwaarde in Vlaamse Wetenschap voor Zorg, the Fonds voor Meerwaarde in Vlaamse Wetenschap voor Zorg, the Fund for Scientific Research-Flanders, the Research Foundation-Flanders, the Belgian Federal Science Policy Office (IAP), and the Interuniversity Attraction Poles (IUAP).
References

1. Cole TJ (2003) The secular trend in human physical growth: a biological view. Econ Hum Biol 1: 161–168.
2. Ogden CL, Fryar CD, Carroll MD, Flegal KM (2004) Mean body weight, height, and body mass index among adults: United States, 1960–2000. Adv Data 1: 1–17.
3. Macgregor S, Cornes BK, Martin NG, Vischer PM (2006) Bias, precision and inheritability of self-reported and clinically measured height in Australian twins. Hum Genet 120: 571–580.
4. Preche MA (1996) The genetic contribution to stature. Hum Res 45 Suppl 2: 56–58.
5. Silventoinen K, Kaprio J, La Helena E, Koskenvuo M (2000) Relative effect of genetic and environmental factors on body height: differences across birth cohorts among Finnish men and women. Am J Public Health 90: 627–630.
6. Silventoinen K, Sammalisto S, Perola M, Boomsma DI, Cornes BK, et al. (2003) Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res 6: 399–408.
7. Perola M, Sammalisto S, Hiekkanen T, Martin NG, Vischer PM, et al. (2007) Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci. PLoS Genet 3: e97. doi:10.1371/journal.pgen.0030099.
8. Vischer PM, Medland SE, Ferreira MA, Molvry KI, Zhu G, et al. (2006) Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. PLoS Genet 2: e41. doi:10.1371/journal.pgen.0020044.
9. Weedon MN, Frayling TM (2008) Reaching new heights: insights into the genetics of human stature. Trends Genet 24: 595–603.
10. Guldhardsson DF, Walters GB, Thorleifsson G, Stefansson H, Hallgrimsson BV, et al. (2008) Many sequence variants affecting diversity of adult human height. Nat Genet 40: 609–615.
11. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, et al. (2008) Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 40: 575–583.
12. Davey Smith G, Hart C, Upton M, Hole D, Gillis C, et al. (2000) Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality. J Epidemiol Community Health 54: 97–103.
13. Lawlor DA, Ebrahim S, Davey Smith G (2002) The association between components of adult height and Type II diabetes and insulin resistance: British Women’s Heart and Health Study. Diabetologia 45: 1097–1106.
14. Lawlor DA, Taylor M, Davey Smith G, Gunnell D, Ebrahim S (2004) Associations of components of adult height with coronary heart disease in postmenopausal women: the British women’s heart and health study. Heart 90: 743–749.
15. Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, et al. (2001) Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 23: 313–342.
16. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, et al. (2007) Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. PLoS Genet 3: e97. doi:10.1371/journal.pgen.0030099.
17. Southam L, Rodriguez-Lopez J, Wilkins JM, Pombo-Suarez M, Snelling S, et al. (2008) Inbreeding Depression on Height.
liver in a genetically isolated population: the Erasmus Rucphen Family Study. Eur J Epidemiol 22: 99–105.

59. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 41: 47–55.

60. Eldon BJ, Axelson J, Sigurdsson SB, Arnason E (2001) Cardiovascular risk factors and relatedness in an Icelandic subpopulation. Int J Circumpolar Health 60: 499–502.

61. Purcell S (2007) PLINK v1.0 whole genome association analysis toolset. 1.0 ed.

62. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

63. Aulchenko YS (2008) GenABEL Tutorial. Available: http://mgabionetnscru/yuri/courses/ge05-2008/GenABEL-tutorialpdf. Accessed 2011.

64. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM (2007) GenABEL: an R library for genome-wide association analysis. Bioinformatics 23: 1294–1296.

65. Aulchenko Y (2012) GenABEL.org Manuals. Available: http://wwwgenabelorg/manuals/GenABEL/polygenichtml. Accessed 2012.